Regeneron Pharmaceuticals v. Merus N.V., No. 16-1346 (Fed. Cir. July 27, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Regeneron Pharmaceuticals, Inc. (“Regeneron”) a p- peals from a final judgment of the district court holding U.S. Patent No. 8,502,018 (“’018 p atent”) u nenforceable because of Regeneron’s inequitable co nduct during prose- cution. Regeneron also appeals the district court’s co n- struction of several claim terms and determination of indefiniteness. Because we conclude that Regeneron engaged in inequitable conduct during prosecution of the ’018 patent, we affirm.